US 12,168,696 B2
Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer
David Spriggs, New York, NY (US); Javier Morales, Emeryville, CA (US); Yoko Nakano, Emeryville, CA (US); and Hong Liu, Emeryville, CA (US)
Assigned to Memorial Sloan Kettering Cancer Center, New York, NY (US); and Eureka Therapeutics, Inc., Emeryville, CA (US)
Appl. No. 17/292,749
Filed by Memorial Sloan Kettering Cancer Center, New York, NY (US); and Eureka Therapeutics, Inc., Emeryville, CA (US)
PCT Filed Nov. 14, 2019, PCT No. PCT/US2019/061503
§ 371(c)(1), (2) Date May 11, 2021,
PCT Pub. No. WO2020/102555, PCT Pub. Date May 22, 2020.
Claims priority of provisional application 62/768,730, filed on Nov. 16, 2018.
Prior Publication US 2021/0403597 A1, Dec. 30, 2021
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/3092 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01)] 15 Claims
 
1. An anti-mucin 16 (MUC16) construct comprising an antibody moiety that immunospecifically recognizes a mucin 16 (MUC16) polypeptide, wherein the antibody moiety comprises:
(a) (i) a variable heavy (VH) chain comprising a heavy chain complementarity determining region (HC-CDR) 1, a HC-CDR2, and a HC-CDR3 of the heavy chain variable domain of SEQ ID NO: 2; and
(ii) a variable light (VL) chain comprising a light chain complementarity determining region (LC-CDR) 1, a LC-CDR2, and a LC-CDR3 of the light chain variable domain of SEQ ID NO: 3;
or
(b) (i) a variable heavy (VH) chain comprising a heavy chain complementarity determining region (HC-CDR) 1, a HC-CDR2, and a HC-CDR3 of the heavy chain variable domain of SEQ ID NO: 10; and
(ii) a variable light (VL) chain comprising a light chain complementarity determining region (LC-CDR) 1, a LC-CDR2, and a LC-CDR3 of the light chain variable domain of SEQ ID NO: 11, optionally wherein the antibody moiety
immunospecifically binds to the ectodomain of MUC16; or
comprises human-derived heavy and light chain constant regions; or
is an immunoglobulin comprising two identical heavy chains and two identical light chains, optionally wherein the immunoglobulin is an IgG, or
is a full-length antibody, a monoclonal antibody, a Fab, a Fab′, a F(ab′)2, an Fv, or a single chain Fv (scFv).